Stock Watch: Class Of 2016 FDA Approvals Seller Beware: Ignore Your Market At Your Peril 08 Jun 2021 • By Andy Smith Revenues are still elusive for a surprising number of the novel drugs approved by the FDA five years ago. Emergent safety issues and confirmatory clinical trial failures were less common than lack of competitiveness as the main reason for revenue weakness. ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS
H/C analyst after Principal in pricing & market access, H/C fund manager, Scrip columnist & pharma. The other half of the smithandsheridan.eu podcast
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Andy Smith
Stockwatch: Teva And Mylan Hit Terminal Velocity
Stockwatch: Teva And Mylan Hit Terminal Velocity 30 Aug 2016 • By Andy Smith Another social media jump on the drug pricing bandwagon by Hillary Clinton directed at Mylan's EpiPen pricing policy temporarily sank most life science stock prices last week. Fortunately, the lasting impact should be limited to Teva and Mylan. Hillary Clinton's Comments Hit Mylan Stock • Source: Shutterstock: akatz
Our #empowerindependents campaign meets MP Justin Tomlinson
Our campaign to #empowerindepdents took us to Swindon today where our MD, Nick Summers and Head of Marketing, Roxy Bentley met with Justin Tomlinson after NCASS member, James from Gurt Wings sent the MP for North Swindon our MP letter template. Justin Tomlison was more than happy to meet with us to discuss tax reform for hospitality businesses as set out in our campaign, letters to the Chancellor and discussions with the Minister for Hospitality.
WISA Addresses Sustainability at Annual Summit
“A sustainable future for the air transport sector will be inextricably linked to technological innovations and the development of a future-ready workforce.” So said Dr. Suzanne Kearns, Founding Director of the Waterloo Institute for Sustainable Aeronautics (WISA) announcing the Sustainable Aeronautics Summit on October 25th in Kitchener, Ontario.
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Positive Trial Announcements Need A Pinch Of Salt
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Pharma Castoffs Sink Without A Trace ... Eventually
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: The Competition Has It
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: The Great Post-Pandemic Pharmaceutical Marketing Debate
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Non-COVID-19 Vaccines Under The Pandemic
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Bridgebio's Endpoint A Bridge Too Far
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Drug Safety In The Spotlight
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: All Roads Lead Back To Pricing In Biogen And J&J's Third-Quarter Earnings
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Dam Cracks After A Trickle Of Failed Pandemic Products
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Donanemab Provides Cover For Lilly's Second-Quarter Insulin Challenge
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Investors Reward Those Who Raise Their Guidance
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Poxel Passes Go...But To Where?
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Why Have Biotech Acquisitions Paused?
UsernamePublicRestriction Your username does not meet the requirements. Sorry - this email domain is not allowed. Sorry - public email accounts are not allowed. Please provide a work email address. An account with that username already exists. Unfortunately we've not been able to process your registration. Please contact support. SC144701 Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch. Thank you for submitting your question.
Stock Watch: Not So Fast, Gene Editors
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Post-Pandemic Life Science Market Dynamics
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Class Of 2016 FDA Approvals
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Veklury Peaks And Leaves Gilead In The Lurch
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: Pandemic Lessons For Smaller Commercial Biotechs
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: The Rise Of Vaccine Cannibalism
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: The Two Sides Of A Complete Response Letter
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stock Watch: J&J And Roche Invite Comparison
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stockwatch: Reading The Tea Leaves For Pharma Q1 Earnings
Ask The Analyst Email Print Bookmark Diagnostics Companies’ Pre-Announcements Presage Pressures On Drug Revenues 19 Apr 2021 Opinion Executive Summary Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies. You may also be interested in...
Stockwatch: The Two Sides Of A Complete Response Letter
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stockwatch: Unconventional Biosimilar Wisdom
Ask The Analyst Email Print Bookmark Tags: Biosimilars Stockwatch Companies Don't Assume The US Is Easier For Innovator Product Defenders 06 Apr 2021 Opinion Executive Summary Conventional wisdom from the first biosimilar launches was that the European market that was far tougher on innovator products than was the US. More recent data suggest that things may play out differently in the long run. You may also be interested in...
Stockwatch: The Complex Biologics Market Is...Complex
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stockwatch: Amphastar's Turn Away From Generics
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stockwatch: Like Moths To The Unvalidated Flame
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stockwatch: Should A Biotech's First Product Be Out-Licensed Or Self-Marketed?
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Stockwatch: The Pandemic - Where Generics Failed To Reign
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Fixing racial injustice, failing schools remain priorities in Providence
PLENTY ON HIS PLATE: Providence Mayor Jorge O. Elorza is not only leading the city government through the COVID-19 pandemic, but he’s also signed an executive order to start a truth-telling and reparation process for Black and Indigenous people. / PBN PHOTO/MICHAEL SALERNO Mayor Jorge O. Elorza has been in office since 2015, but after being reelected in 2018, he is now term-limited and cannot run for mayor of Providence again in 2022.
FAA Docket Filings for December 17, 2020
Joshua James Flores - Exemption/Rulemaking FAA-2020-1047 FAA-2020-1047-0002 December 17, 2020 Get Filing Here Get Filing Here Regulations.gov Docket Page Docket Page Decision See attached file Airobotics Inc., Model OPTIMUS 1-EX Unmanned Aircraft System, Special Class Airworthiness Criteria FAA-2020-1092 FAA-2020-1092-0011 December 17, 2020 Get Filing Here Regulations.gov Docket Page Docket Page THC/San Jacinto Battleground SHS See attached file(s) Organization: THC/San Jacinto Battleground...
Hartigan’s fully invested in fintech firm she created
CREATIVE CAPITAL: Margaret Hartigan, co-founder and CEO of Marstone, a digital financial platform with offices in Providence, speaks with Benjamin Baker, head of sales. Hartigan says she chose to base her company in Providence because of the “incredible level of creativity and diversity here.” / PBN PHOTO/MICHAEL SALERNO Margaret Hartigan found a lot to like about Providence.
PBN panelists: Companies need top-level commitment to break diversity, inclusion barriers
DIVERSE DISCUSSION: Panelists discuss the evolution of diversity and inclusion initiatives in the workplace at Providence Business News’ Diversity & Inclusion Summit & Awards Program at the Crowne Plaza Providence-Warwick in Warwick on Dec. 5. From left: moderator PBN Editor Michael Mello, Guillaume Bagal, Marianne Monte, Kim Lee and Nirva LaFortune.
Stockwatch: Oscillating fortunes
ASK THE ANALYST Email Print Bookmark This article was originally published in Scrip 28 Jul 2015 News Executive Summary For some companies reporting their second-quarter earnings, last week was one of fluctuating fortunes. What the market gave to their share prices on one day it took away the next, and running through earnings season was that consistently big subtraction – the effect of foreign currency translations – and the concern that it may yet accelerate. Already Registered?
Stockwatch: Biogen's belligerent repetition
ASK THE ANALYST Email Print Bookmark This article was originally published in Scrip 08 Dec 2014 News Executive Summary Two iconic artists are brought together in unlikely combination at an exhibition that opens in Oxford this week. The patterns of William Morris's curtains and wallpapers have a sublime connection with Andy Warhol's prints of Marilyn Monroe – repetition. The theme of repetition also struck me in the most impactful clinical data release of last week. Already Registered?
Thrall (Prime Earth) 002.jpg
Size of this preview: 396 × 479 pixels. Other resolutions: 198 × 240 pixels | 396 × 480 pixels | 495 × 600 pixels | 634 × 768 pixels. About File History Metadata Summary Thrall (Prime Earth) 002.jpg Image Contents Subjects Thrall (Prime Earth) (Images) Khalid Ben-Hassin (Earth 2) (Images) Image Source Source Earth 2 #31 (April, 2015) Image Details Description Thrall (Prime Earth): Used for purposes of illustration in an educational article about the entity represented by the image.
Thrall (Prime Earth) 001.jpg
Size of this preview: 316 × 479 pixels. Other resolutions: 158 × 240 pixels | 317 × 480 pixels | 396 × 600 pixels | 507 × 768 pixels. About File History Metadata Summary Thrall (Prime Earth) 001.jpg Image Contents Subjects Thrall (Prime Earth) (Images) Khalid Ben-Hassin (Earth 2) (Images) Image Source Source Earth 2 #31 (April, 2015) Image Details Description Thrall (Prime Earth): Used for purposes of illustration in an educational article about the entity represented by the image.
Stockwatch: Flat Is The New Black For Lilly And Sanofi
ASK THE ANALYST Email Print Bookmark 13 Feb 2017 Opinion Executive Summary A lackluster fourth-quarter earnings season at least didn't get any worse with the reports of Merck, Lilly, Sanofi and GSK. Flat earnings guidance might be considered to be an improvement on guidance cuts, but financial guidance that depends on currency effects and the absence of generic competition may ultimately be unreliable. Already Registered? Sign in to continue reading. New to Scrip?
Stockwatch: Mistaken Acquisitions Dim Earnings Season
UsernamePublicRestriction Your username does not meet the requirements. Sorry - this email domain is not allowed. Sorry - public email accounts are not allowed. Please provide a work email address. An account with that username already exists. Unfortunately we've not been able to process your registration. Please contact support.
Stockwatch: Pricing Delusions Of Blockbuster Proportions
UsernamePublicRestriction Your username does not meet the requirements. Sorry - this email domain is not allowed. Sorry - public email accounts are not allowed. Please provide a work email address. An account with that username already exists. Unfortunately we've not been able to process your registration. Please contact support.
Stockwatch: Valeant Attempts To Divert Attention
ASK THE ANALYST Email Print Bookmark Tags: Commercial Companies Deals 16 Jan 2017 Opinion Executive Summary A well-orchestrated build-up to the annual J.P. Morgan Healthcare Conference and subsequent rush of fundraisings was helped by the acquisition of Ariad by Takeda early last week. But the good times were derailed by a drug-pricing diversion, unleashed by the US president-elect. Already Registered? Sign in to continue reading. New to Scrip?
Stockwatch: What Links Actimmune And Vertex’s Event Horizon?
ASK THE ANALYST Email Print Bookmark 12 Dec 2016 Opinion Executive Summary Drug failures in Phase III and value-based pricing were two forces affecting Horizon and Vertex, respectively, last week. Biogen and Teva have shown that value, at least, is a force to be argued with. Already Registered? Sign in to continue reading. New to Scrip?
Stockwatch: Bluebird, Arrowhead And Short Memories
ASK THE ANALYST Email Print Bookmark 05 Dec 2016 Opinion Executive Summary Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno. Already Registered? Sign in to continue reading. New to Scrip?
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Andy
Contact Andy, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack